d-Chiro-inositol and its significance in polycystic ovary syndrome: a systematic review

References

• Goldenberg N, Glueck C. Medical therapy in women with polycystic ovarian syndrome before and during pregnancy and lactation. Minerva Ginecol 2008;60:63–75.
   PubMedGoogle Scholar
• Boomsma CM, Fauser BC, Macklon NS. Pregnancy complications in women with polycystic ovary syndrome. Semin Reprod Med 2008;26:72–84.
   PubMed Web of Science ®Google Scholar
• Palacio JR, Iborra A, Ulcova-Gallova Z, Badia R, Martínez P. The presence of antibodies to oxidative modified proteins in serum from polycystic ovary syndrome patients. Clin Exp Immunol 2006;144:217–222.
   PubMed Web of Science ®Google Scholar
• Lobo RA A disorder without identity: “HCA,” “PCO,” “PCOD,” “PCOS,” “SLS.” what are we to call it?! Fertil Steril 1995;63:1158–1159.
   PubMedGoogle Scholar
• Koivunen R, Laatikainen T, Tomás C, Huhtaniemi I, Tapanainen J, Martikainen H. The prevalence of polycystic ovaries in healthy women. Acta Obstet Gynecol Scand 1999;78:137–141.
   PubMed Web of Science ®Google Scholar
• Boomsma CM, Fauser BC, Macklon NS. Pregnancy complications in women with polycystic ovary syndrome. Semin Reprod Med 2008;26:72–84.
   PubMed Web of Science ®Google Scholar
• Baillargeon JP, Iuorno MJ, Nestler JE. Insulin sensitizers for polycystic ovary syndrome. Clin Obstet Gynecol 2003;46:325–340.
   PubMed Web of Science ®Google Scholar
• Nestler JE. Role of hyperinsulinemia in the pathogenesis of the polycystic ovary syndrome, and its clinical implications. Semin Reprod Endocrinol1997;15:111–122.
   PubMedGoogle Scholar
• De Leo V, la Marca A, Petraglia F. Insulin-lowering agents in the management of polycystic ovary syndrome. Endocr Rev 2003;24:633–667. Review.
   PubMed Web of Science ®Google Scholar
• Tang T, Lord JM, Norman RJ, Yasmin E, Balen AH. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, d-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst Rev 2010;20:CD003053. Review.
   Google Scholar
• Diamanti-Kandarakis E, Christakou CD, Kandaraki E, Economou FN. Metformin: an old medication of new fashion: evolving new molecular mechanisms and clinical implications in polycystic ovary syndrome. Eur J Endocrinol 2010;162:193–212. Review.
   PubMed Web of Science ®Google Scholar
• Leeman L, Acharya U. The use of metformin in the management of polycystic ovary syndrome and associated anovulatory infertility: the current evidence. J Obstet Gynaecol 2009;29:467–472. Review.
   PubMedGoogle Scholar
• Sun TH, Heimark DB, Nguygen T, Nadler JL, Larner J. Both myo-inositol to chiro-inositol epimerase activities and chiro-inositol to myo-inositol ratios are decreased in tissues of GK type 2 diabetic rats compared to Wistar controls. Biochem Biophys Res Commun 2002;293:1092–1098.
   PubMed Web of Science ®Google Scholar
• Suzuki S, Kawasaki H, Satoh Y, Ohtomo M, Hirai M, Hirai A, Hirai S, Onoda M, Matsumoto M, Hinokio Y. Urinary chiro-inositol excretion is an index marker of insulin sensitivity in Japanese type II diabetes. Diabetes Care 1994;17:1465–1468.
   PubMed Web of Science ®Google Scholar
• Larner J, Craig JW. Urinary myo-inositol-to-chiro-inositol ratios and insulin resistance. Diabetes Care 1996;19:76–78.
   PubMed Web of Science ®Google Scholar
• Larner J, Huang LC, Schwartz CF, Oswald AS, Shen TY, Kinter M, Tang GZ, Zeller K. Rat liver insulin mediator which stimulates pyruvate dehydrogenase phosphate contains galactosamine and d-chiroinositol. Biochem Biophys Res Commun 1988;151:1416–1426.
   PubMed Web of Science ®Google Scholar
• Baillargeon JP, Iuorno MJ, Apridonidze T, Nestler JE. Uncoupling between insulin and release of a d-Chiro-Inositol-Containing Inositolphosphoglycan mediator of insulin action in obese women with Polycystic Ovary Syndrome. Metab Syndr Relat Disord, in press.
   Google Scholar
• Nestler JE, Jakubowicz DJ, Reamer P, Gunn RD, Allan G. Ovulatory and metabolic effects of d-chiro-inositol in the polycystic ovary syndrome. N Engl J Med 1999;340:1314–1320.
   PubMed Web of Science ®Google Scholar
• Baillargeon JP, Iuorno MJ, Jakubowicz DJ, Apridonidze T, He N, Nestler JE. Metformin therapy increases insulin-stimulated release of d-chiro-inositol-containing inositolphosphoglycan mediator in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004;89:242–249.
   PubMed Web of Science ®Google Scholar
• Cheang KI, Baillargeon JP, Essah PA, Ostlund RE Jr, Apridonize T, Islam L, Nestler JE. Insulin-stimulated release of d-chiro-inositol-containing inositol-phosphoglycan mediator correlates with insulin sensitivity in women with polycystic ovary syndrome. Metabolism 2008;57:1390–1397.
   PubMed Web of Science ®Google Scholar
• Baillargeon JP, Nestler JE, Ostlund RE, Apridonidze T, Diamanti-Kandarakis E. Greek hyperinsulinemic women, with or without polycystic ovary syndrome, display altered inositols metabolism. Hum Reprod 2008;23:1439–1446.
   PubMed Web of Science ®Google Scholar
• Iuorno MJ, Jakubowicz DJ, Baillargeon JP, Dillon P, Gunn RD, Allan G, Nestler JE. Effects of d-chiro-inositol in lean women with the polycystic ovary syndrome. Endocr Pract 2002;8:417–423.
   PubMedGoogle Scholar
• Gerli S, Mignosa M, Di Renzo GC. Effects of inositol on ovarian function and metabolic factors in women with PCOS: a randomized double blind placebo-controlled trial. Eur Rev Med Pharmacol Sci 2003;7:151–159.
   PubMedGoogle Scholar
• Baillargeon JP, Diamanti-Kandarakis E, Ostlund RE Jr, Apridonidze T, Iuorno MJ, Nestler JE. Altered d-chiro-inositol urinary clearance in women with polycystic ovary syndrome. Diabetes Care 2006;29:300–305.
   PubMed Web of Science ®Google Scholar
• Nestler JE, Jakubowicz DJ, Evans WS, Pasquali R. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med 1998;338:1876–1880.
   PubMed Web of Science ®Google Scholar
• Nestler JE, Jakubowicz DJ. Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17a activity and serum androgens. J Clin Endocrinol Metab 1997;82:4075–4079.
   PubMed Web of Science ®Google Scholar
• Insmed Incorpoated. Insmed Discontinues Internal Development of INS-1 for Diabetes and Polycystic Ovary Syndrome. (http://investor.insmed.com/releasedetail.cfm?ReleaseID=125212).
   Google Scholar